Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care

Dr. Hans Hammers is a distinguished professor in the Department of Internal Medicine at UT Southwestern Medical Center. He is also a co-leader for clinical research and immunotherapy in the Kidney Cancer Research Program, as well as the Experimental Therapeutics Program.

In this exclusive interview, Dr. Hammers provides insight into his journey as a leading expert in kidney cancer research and immunotherapy. He discusses the pivotal clinical trials he has led that have significantly impacted outcomes for patients with kidney cancer and shares his perspectives on the future of novel immunotherapies and targeted therapies.

Latest News

Nomogram Predicts Probability of Extraurothelial Recurrence in UTUC After RNU

Emily MenendezUpper Tract Urothelial Carcinoma | September 22, 2023

The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.

EV-302: EV Plus Pembrolizumab Improves OS, PFS in Untreated, Advanced Urothelial Carcinoma

Zachary BessetteAdvanced Urothelial Carcinoma | September 22, 2023

The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.

Dr. Petros Grivas Shares What He's Looking Forward to The Most at The Uromigos: Live & Unplugged 2023

Petros Grivas, MD, PhDUromigos Live 2023 | September 21, 2023

Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.

FDA Grants Priority Review to Belzutifan in Previously Treated Advanced RCC

Zachary BessetteAdvanced Renal Cell Carcinoma | September 20, 2023

The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.

Association of Squamous Histology and Clinical Outcomes, Molecular Profiling in mUC

Ivan de Kouchkovsky, MDAdvanced Urothelial Carcinoma | September 19, 2023

Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.

Examining Squamous Urothelial Carcinoma Responsiveness to Novel Therapies

Ivan de Kouchkovsky, MDAdvanced Urothelial Carcinoma | September 19, 2023

Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.

AUA Amendment to Testicular Cancer Guideline Includes New Treatment Options, Imaging Recommendations

Emily MenendezTesticular, Penile, and Rare Malignancies | September 15, 2023

The AUA released a new amendment to their 2019 guideline for the diagnosis and treatment of early-stage testicular cancer.

EV-301 2-Year Follow-up Shows Consistent Benefit of EV Over Chemotherapy for Urothelial Carcinoma

Emily MenendezAdvanced Urothelial Carcinoma | September 15, 2023

The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.

SEER Database Helps Determine OS Outcomes of Renal Medullary Carcinoma

Emily MenendeznccRCC | September 14, 2023

Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.

Study Identifies Risk Factors for Stage I Seminoma Relapse

Emily MenendezTesticular, Penile, and Rare Malignancies | September 13, 2023

Newly identified risk factors could be used in future studies on risk-adapted follow-up and treatment strategies.

Low PNI May Indicate Poor Treatment Response in Patients With mHSPC Undergoing ADT

Emily MenendezmHSPC | September 13, 2023

The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.

Novel Theranostic Radiopharmaceutical Detects Lesions in Patients With PSMA PET-Negative BCR Prostate Cancer

Zachary BessetteNext-Generation Imaging | September 13, 2023

Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.

Editorial Advisory Board

Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center

Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital

Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine

Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles

Akhil Abraham Saji, MDAssociate Editor | Fellow at the University of Southern California

David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center

Expert Interviews

Precision Therapy for MIBC: Novel Treatments Helping, Biomarkers Lacking

Guru P. Sonpavde, MDMuscle Invasive Urothelial Carcinoma | August 24, 2023

Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.

Emerging Targeted Therapies in Bladder Cancer: Frontline Options and Beyond

Arlene O. Siefker-Radtke, MDAdvanced Urothelial Carcinoma | May 26, 2023

Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.

Pavlos Msaouel, MD, PhD – Leading the Way in Renal Medullary Carcinoma

Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | May 18, 2023

Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.

Dr. Katherine Virgo on the Updated Guideline for mCRPC

Katherine Virgo, PhD, MBAExpert Interviews | May 2, 2023

Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.

MUSIC and Increasing Active Surveillance for Prostate Cancer: An Interview With Arvin George, MD

David Ambinder, MDProstate Cancer | March 31, 2023

Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.

Maha Hussain on the ARASENS Trial: Darolutamide Plus ADT, Docetaxel for mHSPC

Emily MenendezExpert Interviews | March 30, 2023

A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer

Localized Prostate Cancer

mCRPC

Phenotypic Precision Medicine in Advanced Prostate Cancer

RLT-PSMA

Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Testicular, Penile, and Rare Malignancies

Urothelial Carcinoma

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Prostate Cancer

Localized Prostate Cancer

mCRPC

Phenotypic Precision Medicine in Advanced Prostate Cancer

GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.

Get research and breaking news straight to your inbox.

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 262: Paper of the Month - Abiraterone +/- Cabazitaxel in CRPC

Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.

# Posted on September 14, 2023

# Uromigos-Paper of the Month

# Uromigos-Prostate Cancer

Episode 261: ctDNA in Urothelial Studies Part 2

Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.

# Posted on September 7, 2023

# Uromigos-Bladder Cancer

Episode 260: Celeste Simon: How to Make a Career in Translational Science Work

Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania.

# Posted on September 1, 2023

# Uromigos-Kidney Cancer

Conference Coverage

Live meeting highlights

Dr. Petros Grivas Shares What He's Looking Forward to The Most at The Uromigos: Live & Unplugged 2023

Petros Grivas, MD, PhDUromigos Live 2023 | September 21, 2023

Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.

Get Ready for the Second Annual Uromigos: Live & Unplugged Event

Emily MenendezUromigos Live 2023 | August 29, 2023

The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.

Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC

Ajitha Kommalapati, MDASCO 2023 | August 15, 2023

Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.

Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities

Shilpa Gupta, MDASCO 2023 | August 4, 2023

Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices. Featuring the most current information from around the specialty, it offers insights and exclusive interviews from experts in the field.

Cancer Nursing Today delivers critical news and information to support oncology nurses throughout their education and careers, with the goal of advancing oncology treatments and care and promoting the nurse’s role in enhanced patient outcomes and quality of life.

Urban Health Today is the leading independent news source that provides urban healthcare professionals with relevant clinical news and policy developments that impact patients. Its coverage focuses on clinical, social, and environmental health disparities.

MashupMD is a leading medical news aggregator, optimized for rapid access to the latest headlines in the medical world, providing a collection, or “mashup,” of key medical content based on what your colleagues are reading and sharing on social media.